$2.9 B

KOD Mkt cap, 05-Mar-2020
Kodiak Sciences Net income (FY, 2018)-41.4 M
Kodiak Sciences EBIT (FY, 2018)-26.4 M
Kodiak Sciences Cash, 31-Dec-201888.3 M

Kodiak Sciences Income Statement

Annual

USDFY, 2016FY, 2017FY, 2018

R&D expense

14.1m22.0m18.8m

General and administrative expense

3.1m3.5m7.6m

Operating expense total

17.2m25.5m26.4m

EBIT

(17.2m)(25.5m)(26.4m)

Interest expense

6.0k1.2m5.5m

Net Income

(17.1m)(27.9m)(41.4m)

Kodiak Sciences Balance Sheet

Annual

USDFY, 2017FY, 2018

Cash

1.4m88.3m

Prepaid Expenses

200.0k2.2m

Current Assets

1.6m90.4m

PP&E

1.5m1.1m

Total Assets

3.2m92.2m

Accounts Payable

3.4m1.1m

Current Liabilities

9.2m4.8m

Total Liabilities

22.0m5.4m

Common Stock

1.0k4.0k

Preferred Stock

50.0m

Additional Paid-in Capital

584.0k197.6m

Total Equity

(68.7m)86.8m

Financial Leverage

0 x1.1 x

Kodiak Sciences Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018

Net Income

(17.1m)(27.9m)(41.4m)

Depreciation and Amortization

257.0k549.0k490.0k

Accounts Payable

23.0k2.3m(2.3m)

Cash From Operating Activities

(16.0m)(17.7m)(29.0m)

Purchases of PP&E

(771.0k)(209.0k)(78.0k)

Cash From Investing Activities

(771.0k)(209.0k)(581.0k)

Long-term Borrowings

(62.0k)(97.0k)(108.0k)

Cash From Financing Activities

(120.0k)9.6m116.5m

Net Change in Cash

(16.9m)(8.2m)86.9m

Kodiak Sciences Ratios

USDY, 2018

Financial Leverage

1.1 x

Kodiak Sciences Operating Metrics

Q2, 2018

Phase I Trials Products

1

Preclinical Phase Products

3